The DUSP11 Knockout HeLa Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, in which the DUSP11 gene has been disrupted to create a loss-of-function model. This heterogeneous pool of gene-edited cells enables researchers to study the functional consequences of DUSP11 deficiency in innate immune signaling pathways without the limitations of clonal selection.
HeLa cells are an epithelial cell line originally isolated from a human cervical adenocarcinoma and have become a cornerstone of biomedical research, particularly in cancer biology, virology, and signal transduction. Their established interferon signaling machinery and susceptibility to viral infection make them an ideal host for investigating innate antiviral responses.
DUSP11 functions as an RNA 5′-triphosphatase that selectively removes the triphosphate group from the 5′ end of RNA molecules, a modification that is recognized by the cytosolic pathogen recognition receptor RIG-I. Disruption of DUSP11 leads to the persistence of 5′-triphosphate RNA species that bind and activate RIG-I and the related sensor MDA5, promoting their interaction with the mitochondrial adaptor MAVS. This interaction nucleates a signaling complex that activates the kinase TBK1, which in turn phosphorylates the transcription factor IRF3. Phosphorylated IRF3 translocates to the nucleus and drives the expression of type I interferons, such as IFN-??, and downstream interferon-stimulated genes, thereby amplifying the innate immune response.
In the context of HeLa cells, loss of DUSP11 unveils a heightened state of innate immune alertness, enabling detailed dissection of the molecular events that govern RIG-I-like receptor signaling and interferon production. This model is particularly valuable for exploring how cancer cells may exploit DUSP11 to dampen antiviral immunity, and for studying the signaling thresholds that distinguish self from non-self RNA, with implications for autoimmune disorders and viral pathogenesis.
Key research applications include monitoring pathway activation through Western blot detection of phospho-IRF3 and secreted IFN-??, assessing transcriptional responses by RT-qPCR for IFN-?? and ISG mRNAs, and quantifying interferon regulatory element activity using luciferase reporter assays. The polyclonal population is also suitable for viral replication kinetics assays and high-throughput screens for agonists or antagonists of RIG-I signaling, supporting both basic immunology and therapeutic discovery. For additional information, please contact Ascent Research.
